aminopeptidas
n
apn
inhibitor
report
effect
treat
life
threaten
diseas
includ
cancer
valid
ligandand
structurebas
pharmacophor
map
approach
combin
bayesian
model
recurs
partit
identifi
structur
physicochem
requir
highli
activ
apn
inhibitor
base
assumpt
ligandand
structurebas
pharmacophor
model
complementari
efficaci
multipl
pharmacophor
screen
filter
true
posit
virtual
hit
investig
multipl
pharmacophor
screen
method
util
search
novel
virtual
hit
apn
inhibit
number
hit
refin
reduc
recurs
partit
druglikeli
pharmacokinet
properti
predict
compar
moleculardock
studi
four
compound
propos
potenti
virtual
hit
apn
enzym
inhibit
aminopeptidas
aminopeptidas
n
apn
ec
zincdepend
membran
type
ii
endopeptidas
belong
famili
clan
metallopeptidas
superfamili
peptidas
contain
amino
acid
rel
molecular
mass
r
apn
mainli
involv
atpdepend
downstream
process
cytosol
protein
degrad
enabl
util
amino
acid
nutrient
enzym
found
varieti
speci
mammal
insect
plant
bacteria
human
apn
ident
human
lymphocyt
surfac
cluster
differenti
antigen
also
known
wide
distribut
mammal
express
surfac
differ
cell
epitheli
cell
intestin
kidney
synapt
membran
central
nervou
system
fibroblast
endotheli
cell
epitheli
cell
sebocyt
keratinocyt
deregul
express
observ
mani
diseas
cancer
chronic
pain
variou
form
joint
effus
rheumatoid
arthriti
multipl
sclerosi
system
sclerosi
system
lupu
erythematosu
apn
play
crucial
role
tumor
invas
metastasi
angiogenesi
cancer
overexpress
apn
report
breast
colon
gastric
ovarian
pancreat
renal
thyroid
cancer
therefor
use
import
clinic
marker
cancer
apn
also
function
receptor
corona
viru
like
gastroenter
viru
human
corona
viru
inhibit
may
use
treatment
diseas
bestatin
first
identifi
apn
inhibitor
isol
streptomyc
olivoreticuli
report
improv
immunolog
function
enhanc
chemotaxi
lymphocyt
although
sever
smallmolecul
inhibitor
synthes
evalu
biolog
far
still
challeng
develop
potent
inhibitor
higher
bind
potenti
efficaci
recent
xray
crystal
structur
human
apn
hapn
complex
bestatin
report
provid
opportun
understand
mechan
action
differ
apn
inhibitor
structurebas
analysi
studi
attempt
made
highlight
structur
physicochem
requir
apn
inhibitor
also
tri
find
novel
scaffold
virtual
hit
design
potent
druglik
apn
inhibitor
ligandand
structurebas
pharmacophor
map
studi
perform
identifi
structur
requir
potent
apn
inhibitori
activ
two
differ
qsar
approach
ie
bayesian
model
recurs
partit
rp
techniqu
adopt
understand
physicochem
structur
requir
better
apn
inhibitori
activ
simultan
multipl
pharmacophorebas
virtual
screen
employ
select
virtual
hit
divers
chemic
databas
best
rp
model
util
select
virtual
hit
ligand
obtain
multipl
pharmacophorebas
virtual
screen
compar
molecular
dock
studi
three
differ
dock
tool
perform
search
potenti
druglik
virtual
hit
well
predict
possibl
interact
propos
virtual
hit
catalyt
residu
bind
site
apn
enzym
data
set
apn
inhibitor
collect
literatur
ic
valu
compound
determin
group
author
use
lleucinepnitroanilid
substrat
microsom
aminopeptidas
n
porcin
kidney
microsom
enzym
data
set
intern
data
set
use
develop
well
preliminari
valid
pharmacophor
model
molecul
data
set
wide
rang
inhibitori
activ
ic
moreov
second
data
set
extern
data
set
contain
compound
collect
bind
databas
bd
unlik
intern
dataset
biolog
activ
compound
determin
variou
assay
method
differ
group
author
apn
inhibitori
activ
molecul
express
either
ic
k
dissoci
constant
inhibitor
bind
bd
compound
compound
arbitrarili
chosen
activ
apn
inhibitor
report
ic
k
compound
arbitrarili
select
inact
apn
inhibitor
report
ic
k
compar
intern
data
set
extern
compound
contain
structur
biolog
activ
variat
purpos
use
extern
data
set
assess
overal
perform
pharmacophor
model
develop
bayesian
rp
model
detail
inform
intern
extern
data
set
compound
provid
support
inform
tabl
respect
one
ligandbas
pharmacophor
two
structurebas
pharmacophor
model
develop
studi
first
structurebas
pharmacophor
gener
ligandreceptor
interact
receptor
cocrystal
ligand
util
model
gener
second
structurebas
pharmacophor
built
receptor
structur
use
inform
bind
site
interact
pharmacophor
model
independ
gener
valid
use
differ
protocol
accelri
discoveri
studio
ds
ligandbas
pharmacophor
model
model
qsar
pharmacophor
model
develop
hyporefin
modul
ds
method
structur
divers
compound
logarithm
biolog
activ
rang
approxim
select
intern
dataset
help
find
divers
molecul
protocol
ds
fingerprint
featur
fingerprint
maximum
diamet
biolog
activ
valu
ic
use
properti
select
divers
molecul
compound
subsequ
use
train
set
gener
ligandbas
pharmacophor
hypothes
compound
initi
minim
smart
minim
protocol
ds
appli
steepest
descent
algorithm
follow
conjug
gradient
algorithm
prior
pharmacophor
gener
featur
map
tool
use
predict
favor
featur
highli
activ
compound
also
found
addit
exclus
volum
e
improv
overal
statist
qualiti
model
moreov
uncertainti
valu
fix
divers
set
conform
compound
gener
use
fast
conform
gener
method
maximum
number
conform
energi
rang
chosen
kcalmol
respect
develop
pharmacophor
hypothes
valid
three
differ
method
cost
analys
fischer
random
test
test
set
predict
cost
analysi
method
three
cost
valuesfix
total
null
cost
gener
hypothes
analyz
fix
ideal
cost
cost
simpl
possibl
hypothesi
fit
data
perfect
manner
null
cost
correl
cost
cost
hypothesi
without
featur
valu
total
cost
gener
hypothesi
lie
fix
cost
null
cost
close
fix
cost
valu
away
null
cost
valu
correl
coeffici
root
mean
squar
deviat
rmsd
configur
cost
paramet
consid
cost
analysi
configur
cost
determin
complex
hypothesi
less
rmsd
valu
explain
qualiti
correl
experiment
estim
valu
less
standard
pharmacophor
hypothesi
fischer
random
test
use
ensur
whether
strong
correl
exist
chemic
structur
biolog
activ
train
set
compound
test
perform
confid
level
biolog
activ
train
set
data
scrambl
use
featur
paramet
use
develop
origin
hypothesi
random
run
produc
hypothesi
better
correl
coeffici
andor
less
total
cost
origin
hypothesi
may
consid
develop
chanc
third
valid
method
ie
test
set
predict
use
ensur
pharmacophor
hypothes
well
predict
set
divers
compound
train
set
compound
test
set
contain
compound
subject
ligand
pharmacophor
map
protocol
ds
map
compound
gener
hypothesi
obtain
estim
activ
valu
compound
higher
correl
coeffici
experiment
estim
activ
test
set
indic
better
extern
predict
gener
hypothesi
structurebas
pharmacophor
map
ligandreceptor
interact
model
case
microsom
apn
porcin
kidney
use
assay
compound
apn
porcin
apn
high
sequenc
ident
hapn
overal
activ
site
peptidebind
region
studi
xray
crystal
structur
hapn
use
structurebas
analys
pdb
id
receptorligand
pharmacophor
gener
protocol
ds
allow
extract
inform
ligandprotein
interact
gener
number
hypothes
receptor
structur
prepar
prepar
protein
method
ds
water
molecul
except
select
molecul
play
import
role
ligandreceptor
bind
remov
subsequ
hydrogen
atom
ad
protein
charmm
forcefield
assign
protein
atom
bind
site
cocrystal
bestatin
defin
receptor
activ
site
receptorbound
bestatin
defin
ligand
hypothes
gener
default
chemic
featur
hydrogenbond
acceptor
hydrogen
bond
donor
hydrophob
posit
ioniz
p
neg
ioniz
n
ring
aromat
ra
consid
hypothes
gener
exclud
volum
e
ad
base
locat
atom
protein
hypothes
gener
follow
default
paramet
chosen
minimum
featur
maximum
charg
distanc
maximum
hydrogenbond
distanc
maximum
hydrophob
distanc
maximum
exclus
volum
distanc
minimum
interfeatur
distanc
two
valid
procedur
implement
test
set
valid
select
scorebas
rank
approach
assess
abil
gener
hypothes
discrimin
activ
inact
ligand
activ
compound
ic
least
activ
compound
ic
intern
data
set
select
construct
activ
inact
set
subsequ
allow
map
gener
pharmacophor
queri
follow
paramet
chosen
screeningconform
gener
fast
maximum
conform
energi
threshold
kcalmol
maximum
omit
featur
good
hit
score
gh
score
chosen
critic
criteria
select
best
pharmacophor
gh
score
indic
good
pharmacophor
model
apart
sensit
se
specif
sp
accuraci
acc
consid
import
paramet
detail
gh
se
sp
acc
provid
support
inform
text
select
score
determin
genet
function
algorithm
gfa
model
select
pharmacophor
built
train
set
pharmacophor
model
use
total
number
featur
model
featurefeatur
distanc
bin
valu
descriptor
set
use
find
capsdivers
databas
ds
logarithm
valu
virtual
hit
use
target
higher
valu
select
score
indic
better
model
method
ludi
interact
map
creat
receptor
pdb
id
activ
site
sphere
compris
catalyt
residu
within
distanc
bound
ligand
bestatin
use
interact
gener
protocol
ds
map
consist
possibl
hydrogenbond
acceptor
hydrogenbond
donor
hydrophob
featur
initi
edit
cluster
pharmacophor
tool
ds
util
edit
redund
pharmacophor
featur
catalyt
import
gener
pharmacophor
queri
featur
care
select
basi
inform
report
ligandreceptor
interact
activ
inact
data
set
use
model
use
model
valid
screen
librari
protocol
ds
util
select
optim
pharmacophor
queri
analysi
one
featur
fix
requir
featur
requir
select
input
test
molecul
screen
select
paramet
screen
method
wereminimum
maximum
featur
respect
maximum
subset
pharmacophor
conform
search
method
fast
minimum
interfeatur
distanc
understand
structur
physicochem
factor
respons
potent
apn
inhibitori
activ
two
differ
qsar
model
techniqu
name
bayesian
model
recurs
partit
rp
model
perform
method
reli
activ
profil
compound
activ
inact
numer
experiment
data
therefor
compound
assay
variou
method
biolog
activ
express
differ
unit
could
use
qsar
model
extern
dataset
contain
activ
inact
compound
use
two
studi
extern
data
set
divid
train
test
set
data
set
respect
select
train
test
set
base
fingerprint
maximum
diamet
ensur
applic
domain
test
compound
whole
data
set
subject
princip
compon
analysi
pca
process
biolog
activ
ic
molecul
along
molecular
properti
alogp
mw
nhbd
nhba
nrb
nr
narr
nfr
mpsa
select
number
compon
minimum
varianc
explain
fix
respect
pca
score
plot
test
compound
remain
close
least
one
train
set
compound
unbias
select
trainingtest
set
creat
recurs
partit
model
protocol
ds
use
build
classif
model
rp
tree
consist
intern
node
leaf
intern
node
correspond
test
one
descriptor
leaf
assign
classif
label
model
built
minim
gini
index
divid
compound
branch
detail
protocol
rp
provid
support
inform
text
descriptor
includ
function
class
fingerprint
maximum
diamet
alogp
mw
nrb
nr
narr
nhbd
nhba
mfpsa
use
bayesian
model
gener
use
creat
bayesian
model
protocol
ds
model
predict
test
test
set
compound
develop
pharmacophor
model
use
queri
databas
screen
find
novel
divers
virtual
hit
suitabl
develop
chemic
databas
nci
compound
spec
compound
maybridg
asinex
compound
screen
studi
retriev
compound
higher
fit
valu
filter
drug
likeli
first
compound
test
lipinski
rule
molecular
weight
hydrogenbond
donor
hydrogenbond
acceptor
logp
veber
rule
rotat
bond
polar
surfac
area
sum
hydrogenbond
donor
acceptor
druglikeli
properti
filter
druglik
compound
test
druglik
absorpt
distribut
metabol
excret
adm
properti
calcul
admet
modul
ds
compound
success
pass
filter
method
treat
test
set
compound
activ
predict
best
develop
rp
model
identifi
molecul
possess
structur
physicochem
featur
essenti
apn
inhibit
screen
druglik
virtual
hit
analyz
thoroughli
ligandreceptorbind
affin
three
molecular
dock
tool
libdockd
gold
glide
xray
structur
apn
complex
bestatin
pdb
id
use
dock
studi
bind
site
cocrystal
bestatin
defin
receptor
activ
site
dock
method
selfdock
carri
initi
dock
trial
consid
success
selfdock
could
reproduc
cocrystal
conformationpos
ligand
consider
extent
get
satisfactori
result
selfdock
ligand
crossdock
similarli
compound
show
consist
well
compar
dock
score
three
differ
tool
libdock
gold
glide
propos
final
virtual
hit
libdock
protein
structur
prepar
remov
bound
water
molecul
proton
protein
structur
protein
dielectr
constant
ph
proton
appli
charmm
forcefield
minim
libdockd
dock
ligand
bind
site
guid
polar
apolar
interact
site
known
hotspot
bind
site
sphere
radiu
surround
center
cocrystal
ligand
bestatin
gener
ligand
conform
gener
use
fast
conform
gener
method
consid
maximum
number
conform
util
kcalmol
limit
conform
analysi
default
paramet
kept
unchang
dock
studi
water
molecul
protein
remov
hydrogen
atom
ad
use
gold
protein
prepar
bind
site
defin
radiu
around
bound
inhibitor
dock
calcul
perform
use
goldscor
fit
function
ten
top
score
conform
ligand
consid
end
process
glide
bound
water
molecul
protein
delet
formal
charg
ligand
well
protein
atom
adjust
restrain
minim
hydrogen
protein
done
use
protein
prepar
wizard
forc
field
molecul
dock
prepar
use
ligand
prepar
step
conform
gener
input
ligand
gener
tautom
remov
defect
structur
optim
ligand
geometri
epik
use
gener
possibl
state
ligand
ph
rang
dock
simul
perform
use
glide
oplsaa
forc
field
grid
box
center
centroid
bound
ligand
defin
bind
region
ligand
dock
perform
util
prepar
protein
ligand
input
extra
precis
xp
dock
use
purpos
conjug
gradient
method
step
use
energi
minim
pose
pass
select
initi
pose
score
phase
top
ten
pose
gener
ligand
ligandbas
qsar
pharmacophor
map
twentyf
structur
divers
apn
inhibitor
select
intern
data
set
consid
train
set
compound
develop
pharmacophor
hypothes
hyporefin
method
train
set
compound
list
fig
model
consist
one
p
ra
featur
along
five
exclus
volum
e
fig
repres
result
model
shown
support
inform
tabl
apart
cost
analys
merit
hypothesi
justifi
abil
predict
activ
individu
compound
within
set
purpos
train
set
compound
approxim
classifi
three
differ
categori
activ
ic
less
activ
ic
low
activeinact
ic
compound
train
set
accur
predict
low
error
valu
experiment
estim
ic
test
set
contain
compound
support
inform
tabl
divers
structur
wide
rang
biolog
activ
use
evalu
best
ligandbas
hypothesi
ie
model
relat
experiment
estim
activ
valu
test
set
compound
show
correl
coeffici
r
r
pred
valu
correl
plot
train
test
set
compound
depict
support
inform
fig
observ
estim
activ
test
set
compound
provid
support
inform
tabl
fischer
random
test
confid
support
inform
tabl
show
random
run
could
produc
correl
less
origin
hypothesi
moreov
total
cost
random
run
much
higher
origin
hypothesi
justifi
model
gener
chanc
figur
repres
arrang
pharmacophor
featur
along
interfeatur
distanc
constraint
figur
c
show
map
least
activ
compound
train
set
model
respect
hydroxyl
group
hydroxam
acid
map
upon
featur
secondari
amino
proton
phenyl
group
map
p
ra
featur
respect
phenyl
carbonyl
group
compound
map
upon
ra
featur
respect
fit
valu
respect
observ
highli
activ
compound
train
set
contain
posit
ioniz
primari
amin
group
although
activ
eg
fit
valu
moder
activ
eg
fit
valu
compound
lack
featur
show
consider
apn
inhibitori
activ
compound
contain
amid
group
map
donor
featur
therefor
may
assum
polar
group
addit
posit
charg
group
also
determin
higher
bind
potenti
ligand
xray
crystal
structur
hapn
complex
bestatin
found
apart
catalyt
amino
acid
residu
bound
water
molecul
atom
number
assign
pdb
structur
play
signific
role
receptor
bind
form
bridg
hydrogenbond
interact
intra
inter
ligand
fragment
bestatin
push
deepli
pocket
enzym
amino
group
carbonyl
oxygen
atom
group
form
watermedi
hydrogen
bond
hapn
schemat
represent
ligandreceptor
interact
shown
fig
map
conform
bestatin
model
shown
fig
found
bestatin
could
map
three
four
featur
model
ra
featur
phenyl
ring
could
compar
interact
wherea
p
featur
secondari
amin
proton
could
compar
interact
water
molecul
hydrogenbond
acceptor
featur
carboxyl
group
could
compar
interact
howev
interact
carbonyl
group
hydroxyl
group
could
interpret
current
model
good
predict
qualiti
model
could
infer
map
interact
respons
determin
biolog
activ
intern
data
set
compound
receptorligand
pharmacophor
map
gener
hypothes
base
receptorligand
interact
intern
data
set
compound
compris
activ
inact
result
shown
tabl
evid
tabl
show
accept
result
term
se
sp
acc
gh
score
map
conform
bestatin
pharmacophor
model
shown
fig
hypothesi
contain
two
featur
p
map
function
model
third
featur
map
hydroxyl
group
form
hydrogenbond
interact
water
molecul
figur
justifi
strong
relat
exist
ligandand
structurebas
pharmacophor
model
howev
model
could
explain
hydrogenbond
interact
carbonyl
group
figur
box
repres
spatial
arrang
featur
model
along
interfeatur
distanc
constraint
interact
gener
protocol
gener
total
featur
h
activ
site
bestatinbind
site
enzym
pdb
id
featur
cluster
redund
interact
remov
figur
show
featur
map
ligand
catalyt
site
receptor
molecul
direct
toward
hydroxyl
carbonyl
group
ligand
respect
featur
correspond
water
molecul
play
import
role
ligandreceptor
interact
select
requir
featur
show
consist
result
test
set
valid
notic
map
interact
posit
ioniz
amino
group
fig
found
import
featur
sar
studi
appear
model
intern
test
set
use
model
screen
compound
retriev
found
activ
base
studi
enrich
factor
gh
valu
calcul
detail
provid
support
inform
tabl
gh
valu
justifi
develop
ludibas
pharmacophor
model
consider
select
activ
compound
gener
train
test
data
protocol
ds
creat
train
test
set
compound
respect
applic
domain
set
analyz
pca
pca
score
plot
fig
support
inform
found
test
compound
remain
compar
close
least
one
train
compound
rp
train
set
compound
gener
three
classif
tree
tree
tree
select
best
model
model
basi
receiv
oper
characterist
roc
score
crossvalid
roc
curv
moreov
model
valid
test
set
compound
roc
score
detail
statist
analysi
model
provid
support
inform
tabl
schemat
represent
rptree
model
shown
fig
figur
depict
develop
model
six
select
descriptor
along
cutoff
valu
use
develop
valid
model
demonstr
npa
mfpsa
alogp
phi
hbacount
play
import
role
distinguish
activ
inact
function
descriptor
list
tabl
support
inform
fig
p
valu
win
class
reflect
sampl
weight
mean
activ
stand
inact
model
train
set
contain
activ
inact
compound
activ
sampl
assign
weight
inact
sampl
assign
weight
eg
node
activ
inact
compound
observ
therefor
p
calcul
express
rp
model
npa
total
number
atom
molecul
posit
charg
found
main
classifi
may
correl
fact
posit
ioniz
featur
like
primari
amin
play
import
role
ligandreceptor
interact
physicochem
descriptor
mfpsa
ratio
polar
surfac
area
total
surfac
area
evid
fig
catalyt
site
apn
contain
amino
acid
polar
side
chain
eg
glutam
acid
tyrosin
etc
well
polar
water
molecul
particip
receptorligand
interact
although
model
highlight
import
ioniz
group
sole
determin
higher
activ
molecul
hydrogenbond
acceptor
donor
group
also
play
vital
role
ligandreceptor
interact
therefor
signific
mfpsa
second
major
classifi
model
compound
lack
npa
reconfirm
polar
molecul
consider
import
apn
inhibit
number
hydrogenbond
acceptor
also
found
import
signific
found
pharmacophor
map
approach
addit
alogp
logarithm
octanolwat
partit
coeffici
determin
ghose
crippen
method
found
import
apn
inhibit
compound
lower
cutoff
valu
npa
mfpsa
function
hydrophob
descriptor
may
easili
understood
bind
site
hapn
compris
hydrophob
pocket
hydrophob
interact
residu
like
report
bestatin
addit
two
topolog
kappashap
index
descriptor
phi
appear
model
alphamodifi
shape
index
order
three
phi
molecular
flexibl
index
topolog
descriptor
appear
model
compound
higher
valu
mfpsa
therefor
may
interpret
flexibl
molecul
import
criterion
higher
activ
eight
interpret
descriptor
alogp
mw
nhba
nhbd
nr
narr
mfpsa
one
fingerprint
featur
molecular
function
class
fingerprint
maximum
diamet
use
develop
bayesian
model
train
test
set
use
rp
model
model
valid
use
loo
crossvalid
roc
gener
roc
curv
train
set
provid
support
inform
fig
model
develop
loo
crossvalid
statist
enrich
data
tabl
support
inform
obtain
best
split
valu
calcul
pick
split
reduc
sum
percent
misclassifi
inhibitor
noninhibitor
use
crossvalid
score
compound
best
split
valu
obtain
current
model
model
demarc
highli
activ
compound
nonpot
inhibitor
base
valu
conting
tabl
obtain
calcul
true
posit
tp
true
neg
tn
fals
posit
fp
fals
neg
fn
loo
crossvalid
result
train
set
provid
support
inform
fig
leav
time
roc
concord
specif
sensit
observ
model
fivefold
crossvalid
result
given
support
inform
tabl
base
bayesian
score
top
favor
unfavor
molecular
fingerprint
apn
inhibitori
activ
identifi
identifi
good
bad
fingerprint
shown
support
inform
tabl
five
select
favor
unfavor
fingerprint
list
fig
retriev
fingerprint
bayesian
model
confirm
featur
contain
number
polar
group
favor
pharmacophor
map
rp
model
infer
polar
group
posit
ioniz
featur
play
essenti
role
enzym
inhibit
bayesian
model
reconfirm
polar
moieti
like
amid
carboxyl
acid
phosphinyl
group
favor
function
aromat
moieti
may
intrigu
appear
favor
unfavor
fingerprint
howev
unfavor
aromat
ring
either
attach
polar
residu
exocycl
conjug
function
may
relat
aromat
ring
interest
find
acycl
ring
appear
unfavor
fingerprint
due
lack
featur
posit
charg
polar
ring
aromat
requir
higher
activ
thirtyon
test
set
compound
use
valid
model
produc
roc
score
indic
high
predict
qualiti
select
bayesian
model
result
show
concord
specif
sensit
result
roc
plot
test
set
valid
provid
support
inform
fig
multipl
pharmacophor
screen
valid
pharmacophor
model
ligandand
structurebas
use
screen
databas
contain
larg
number
divers
molecul
find
compound
could
propos
potenti
virtual
hit
ideal
pharmacophor
queri
abl
captur
activ
molecul
select
databas
discard
inact
molecul
therefor
prior
virtual
screen
select
model
properli
assess
decoy
set
valid
popular
wide
use
approach
confirm
overal
specif
model
decoy
set
set
compound
known
activ
compound
combin
inact
decoy
whole
set
screen
select
pharmacophor
queri
select
inact
compound
decoy
set
valid
crucial
unbias
virtual
screen
select
pharmacophor
model
may
repres
either
roc
curv
gh
score
largest
public
avail
databas
decoy
directori
use
decoy
dud
provid
decoy
limit
number
target
absenc
dud
particular
target
select
inact
depend
user
howev
latter
approach
may
two
major
limit
often
presum
inact
decoy
despit
lack
support
evid
b
decoy
select
method
may
lack
transpar
moreov
verdonk
et
al
earlier
demonstr
molecular
properti
may
affect
result
dockingbas
virtual
screen
propos
may
extrapol
pharmacophorebas
virtual
screen
well
accord
verdonk
et
al
suffici
use
random
librari
subset
public
databas
perform
assess
essenti
build
focus
librari
reflect
physicochem
properti
activ
set
verdonk
principl
may
util
select
decoy
current
approach
altern
procedur
adopt
includ
follow
step
select
well
identifi
recogniz
decoy
set
public
databas
ie
bd
consider
less
focus
intern
dataset
use
pharmacophor
model
develop
b
valid
decoy
set
multipl
screen
three
differ
pharmacophor
model
develop
current
studi
c
determin
activ
profil
rp
model
develop
extern
data
set
justif
step
b
c
discuss
support
inform
text
substanti
idea
multipl
screen
extern
data
set
screen
three
differ
pharmacophor
queri
model
shown
fig
ligandbas
pharmacophor
model
model
select
initi
screen
abl
quantifi
estim
activ
screen
ligand
structurebas
model
util
refin
ligand
filter
model
cutoff
fit
valu
set
model
top
activ
compound
includ
bestatin
intern
data
set
show
fit
valu
map
model
tabl
first
screen
model
retriev
virtual
hit
found
seed
known
inact
compound
percentag
known
inact
gradual
lower
subsequ
screen
retriev
virtual
hit
screen
though
model
respect
therefor
may
conclud
number
inact
may
gradual
reduc
multipl
pharmacophor
screen
approach
could
use
screen
public
databas
four
databasesnci
spec
maybridg
asinex
screen
find
potenti
virtual
hit
apn
inhibitori
activ
compound
screen
three
pharmacophor
model
model
shown
fig
model
filter
compound
fit
valu
compound
screen
subsequ
model
remain
compound
compound
subject
lipinski
veber
rule
drug
likeli
adm
properti
employ
human
intestin
absorpt
aqueou
solubl
bloodbrain
barrier
penetr
compound
found
violat
one
lipinski
andor
veber
rule
drug
likeli
adm
properti
thu
reject
remain
compound
subject
rp
predict
necess
appli
rp
predict
may
substanti
work
verdonk
et
al
point
influenc
descriptor
virtual
screen
rp
model
creat
help
descriptor
highlight
overal
structur
requir
apn
inhibit
applic
model
virtual
screen
may
help
reduc
number
inact
virtual
hit
databas
rp
model
model
fig
predict
compound
activ
physicochem
structur
featur
similar
report
highli
activ
apn
inhibitor
final
compound
subject
molecular
dock
studi
predict
bind
affin
explor
interact
dock
method
bound
inhibitor
bestatin
selfdock
catalyt
site
receptor
pdb
id
three
differ
dock
tool
libdock
gold
glide
best
conform
support
inform
fig
bestatin
observ
libdock
method
lowest
selfdock
rmsd
valu
filter
druglik
compound
dock
three
dock
tool
dock
score
compar
bestatin
found
four
compound
show
consist
dock
result
three
molecular
dock
tool
propos
potenti
virtual
hit
apn
inhibit
dockscor
predict
activ
adm
profil
four
compound
shown
tabl
dock
interact
libdockd
pharmacophor
model
map
conform
virtual
hit
provid
support
inform
fig
respect
two
virtual
lead
compound
contain
piperazin
residu
proton
nitrogen
atom
residu
map
posit
ioniz
featur
also
interact
catalyt
amino
acid
residu
flippo
et
al
earlier
investig
quinolin
antimalari
agent
strongli
inhibit
mammalian
apn
enzym
lowest
ic
compound
also
contain
piperazin
moieti
posit
ioniz
group
chelerythrin
natur
product
contain
quaternari
nitrogen
also
show
inhibit
apn
ligandreceptor
interact
compound
report
earlier
apart
posit
ioniz
featur
propos
virtual
hit
also
contain
polar
group
aromat
ring
found
import
apn
inhibitori
activ
virtual
hit
found
form
interact
catalyt
amino
acid
residu
pharmacophor
map
conform
compar
dock
conform
support
inform
fig
current
chemometr
approach
perform
achiev
three
object
highlight
structur
physicochem
factor
import
apn
enzym
inhibit
focu
aspect
multipl
pharmacophor
screen
approach
pharmacophorebas
virtual
screen
propos
new
virtual
hit
apn
inhibit
ligandand
structurebas
pharmacophor
map
rp
bayesian
model
carri
model
properli
valid
achiev
first
object
ligandand
structurebas
pharmacophor
map
suggest
four
featur
posit
ioniz
b
acceptor
c
donor
ring
aromat
essenti
receptorligand
interact
qsar
pharmacophor
model
may
util
predict
bioactiv
ligand
rp
model
perform
divers
set
molecul
show
posit
ioniz
p
featur
may
import
determin
apn
inhibit
increas
polar
molecul
posit
contribut
higher
biolog
activ
besid
hydrophob
relat
ring
aromat
ra
also
found
involv
receptorligand
interact
rp
model
present
cutoff
valu
import
descriptor
demarc
activ
inhibitor
inact
may
util
design
new
molecul
addit
bayesian
model
highlight
favor
unfavor
fingerprint
may
also
util
novel
lead
design
purpos
result
pharmacophor
map
rp
bayesian
model
compar
consist
enough
indic
success
model
approach
explor
second
object
extern
random
data
set
construct
report
apn
inhibitor
avail
public
databas
bd
shown
multipl
screen
ligandand
structurebas
model
may
decreas
number
fals
posit
gradual
even
random
decoy
set
use
recommend
screen
approach
order
avoid
low
enrich
moreov
also
found
ligandand
structurebas
pharmacophor
model
complementari
sequenti
screen
ligandand
structurebas
pharmacophor
queri
gradual
reduc
number
inact
virtual
hit
multipl
screen
follow
rp
predict
reduc
number
fals
posit
hit
composit
approach
screen
also
decreas
number
true
posit
consider
extent
fig
howev
main
success
approach
lie
fact
less
complic
maintain
transpar
term
select
decoy
well
valid
model
last
object
work
search
potenti
virtual
hit
apn
inhibitor
multipl
pharmacophor
screen
follow
rp
predict
carri
public
databas
retriev
virtual
hit
test
druglik
pharmacokinet
properti
filter
virtual
hit
dock
receptor
activ
site
four
compound
show
consist
result
three
differ
dock
tool
ultim
propos
potenti
virtual
hit
virtual
hit
found
contain
essenti
featur
like
posit
charg
polar
ring
aromat
may
help
obtain
use
apn
inhibitor
